Psychosis
Drug research and approvals for psychosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 439 studies of psychosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 439
- Trials authorized in Canada: 7
- FDA orphan approvals: 0
- EU medicines: 0
- Andy's Mind: A Co-created Serious Game for People With Psychosis (PSICOGAME)NCT07946523 · Not applicable · Fundació Sant Joan de Déu · starts Feb 16, 2026
- Clinical High Risk for Psychosis (CHR) CohortNCT07938177 · Not reported · Jijun Wang · starts Aug 10, 2026
- Health Assessment in People With Severe Mental IllnessNCT07931456 · Not reported · University of the Basque Country (UPV/EHU) · starts Apr 17, 2026
- Sequential Treatment Approaches for Treatment-Resistant SchizophreniaNCT07918222 · Phase 3 · Shanghai Mental Health Center · starts Sep 1, 2026
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable SchizophreniaNCT07908680 · Phase 1 · Novartis Pharmaceuticals · starts Nov 4, 2026
- Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory HallucinationsNCT07902518 · Not applicable · Ciusss de L'Est de l'Île de Montréal · starts Sep 10, 2025
- Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 3NCT07900893 · Not applicable · Washington University School of Medicine · starts Dec 1, 2026
- French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic…NCT07881016 · Not applicable · Fondation FondaMental · starts Jun 11, 2026
- Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for…NCT07858565 · Not reported · Bosnalijek D.D · starts Oct 30, 2025
How its trials ended
1,543 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 328 whose ending is known, 51% met their primary endpoint, 9% missed it and 39% stopped early.
- Completed, result not reported72947%
- Ongoing31921%
- Met its primary endpoint16811%
- Status unknown16711%
- Stopped: other or unclear705%
- Stopped: enrollment or feasibility342%
- Missed its primary endpoint312%
- Stopped: funding111%
- Stopped: sponsor or business decision7<1%
- Stopped: lack of efficacy5<1%
- Stopped: safety2<1%
| Apr 7, 2026 | A phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of karxt + karx-ec for the treatment of…Xanomeline-trospium (BMS-986510) / Xanomeline (BMS-986519) | Bristol-Myers Squibb | Pending |
| Feb 4, 2025 | A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of ML-007C-ma for the treatment of hallucinations and delusions…ML-007C-MA | MapLight Therapeutics | Ongoing |
| May 28, 2024 | Open-label extension study to assess the long-term safety and tolerability of karxt in subjects with psychosis associated with Alzheimer's diseaseXanomeline-trospium (KARXT) | Bristol-Myers Squibb | Closed |
| Jan 8, 2024 | A phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of karxt for the treatment of psychosis…Xanomeline-trospium (KARXT) | Bristol-Myers Squibb | Ongoing |
| Aug 4, 2022 | Longitudinal assessment of synaptic density across the psychosis spectrum using the novel synaptic vesicular protein 2a tracer [18f]synvest-1[18F] SDM-8 inj | Centre for Addiction and Mental Health | Ongoing |
| Aug 20, 2021 | Investigating synaptic density in youth at risk for psychosis using the pet tracer [F-18]synvest-1 ([F-18]SMD8[F-18] SDM-8 | Centre for Addiction and Mental Health | Ongoing |
| Aug 1, 2018 | Imaging nociceptin receptors in clinical high risk and first episode psychosis using positron emission tomography with the novel radioligand [11c]NOP-1A[11C]-NOP-1A | Pet Centre Centre for Addiction and Mental Health | Closed |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Jul 25, 2008 | MetyrosineTreatment of velocardiofacial syndrome associated psychosis. | Cerberus Princeton, LLC | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA